Image

Global Atherosclerosis Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Atherosclerosis Market, By Stages (Endothelial Damage and Immune Response, Fatty Streak, Plaque Growth, Plaque Rupture), Diagnosis (Ankle-brachial Index (ABI), Doppler Ultrasound, Echocardiogram, Electrocardiogram (ECG), Blood Tests, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Atherosclerosis Market

Market Analysis and Size

The narrowing of a vein as a result of plaque build-up is known as atherosclerosis. Atherosclerosis is a type of arteriosclerosis that affects the arteries. The condition disrupts the flow of blood throughout the body, posing serious cardiovascular risks. When the endothelium is damaged, LDL cholesterol accumulates in the arterial wall, causing atherosclerosis. To clean up the cholesterol, the body sends macrophage white platelets. However, the cells can sometimes become stuck at the impacted spot. After a period of time, plaque forms, which is made up of bad cholesterol (LDL cholesterol) and macrophage white platelets. The plaque obstructs the corridor, causing the blood flow around the body to be disrupted.

Data Bridge Market Research analyses that the atherosclerosis market was valued at USD 2.55 billion in 2021 and is expected to reach USD 4.11 billion by 2029, registering a CAGR of 6.16% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Stages (Endothelial Damage and Immune Response, Fatty Streak, Plaque Growth, Plaque Rupture), Diagnosis (Ankle-brachial Index (ABI), Doppler Ultrasound, Echocardiogram, Electrocardiogram (ECG), Blood Tests, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy's Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland)

Market Opportunities

 

  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies

Market Definition

The hardening and constriction of your arteries caused by cholesterol plaques lining the artery over time is known as atherosclerosis. Atherosclerosis will be slowed, if not stopped, by drugs for high cholesterol and high blood pressure. They reduce your chances of having a heart attack or a stroke. A doctor can utilize more intrusive procedures to unblock atherosclerotic blockages. Bypass surgery involves diverting blood around a blocked or narrowed artery using a vascular from another part of your body or a synthetic tube. Thrombolytic therapy entails injecting a medication into the afflicted artery to dissolve a blood clot. Plaque is removed from your arteries using a catheter with a sharp blade at one end, which is known as atherectomy.

Atherosclerosis Market Dynamics

Drivers

  • Increasing prevalence of cardiovascular diseases

The rising prevalence of cardiovascular diseases across the globe is estimated to enhance the market's growth. According to the European Heart Network, cardiovascular disease affects 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union. In wealthy countries, sedentary lifestyles are responsible for the highest rates of cardiovascular disease. Also, the market examined is anticipated to be driven by a sedentary lifestyle resulting to a high prevalence of cardiovascular disorders and rising awareness of treatment choices.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to cardiovascular diseases, further estimated to enhance the risk of atherosclerosis in this age group.

  • Rising incidences of high cholesterol and obesity

The rising incidences of obesity and high cholesterol is expected to flourish the market's growth rate by increasing the risk of atherosclerosis. In 2018, the World Health Organization estimates that 40 million children under the age of five were overweight or obese, according to the world health organization (WHO). Increased consumption of high-fat, high-sugar foods and rise in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization are all contributing to high cholesterol rates, resulting in high growth of market.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the atherosclerosis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of atherosclerosis market. Rising level of disposable income and high prevalence of high blood pressure are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the atherosclerosis market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

  • Popularity of Generic Drugs

Due to several recalls of valsartan products manufactured by several brands, the US Food and Medication Administration approved a novel generic drug of Diovan in March 2019 to bridge the high demand and poor supply gap of this vital drug. After two months, Zydus Cadila reported that Chlorthalidone, a generic counterpart of Thalitone made by Pfizer, had been approved. This will create new market opportunities in coming years.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for atherosclerosis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the atherosclerosis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This atherosclerosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the atherosclerosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Atherosclerosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Atherosclerosis Market Scope

The atherosclerosis market is segmented on the basis of stages, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Stages

  • Endothelial Damage and Immune Response
  • Fatty Streak
  • Plaque Growth
  • Plaque Rupture

Diagnosis

Treatment

  • Medication
  • Anti-Platelet Drugs
  • Cholesterol Lowering Medications
  • Beta Blockers
  • Angiotensin-Converting Enzyme (Ace) Inhibitors
  • Calcium Channel Blockers
  • Others
  • Surgery
  • Coronary artery bypass surgery
  • Fibrinolytic therapy
  • Endarterectomy
  • Angioplasty
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Atherosclerosis Market Regional Analysis/Insights

The atherosclerosis market is analysed and market size insights and trends are provided by country, stages, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the atherosclerosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the atherosclerosis market because of the rising prevalence of atherosclerosis and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Atherosclerosis Market Share Analysis

The atherosclerosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to atherosclerosis market.

Some of the major players operating in the atherosclerosis market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Allergan (Ireland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Gilead Sciences, Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • AbbVie Inc. (U.S.)
  • Lupin (India)
  • Allergan (Ireland)

Research Methodology: Global Atherosclerosis Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for atherosclerosis market is expected USD 4.11 billion by 2029.
The Atherosclerosis Market is to grow at a CAGR of 6.16% during the forecast by 2029.
The significant factors flourishing the growth of the Atherosclerosis Market are Increasing prevalence of cardiovascular diseases, and Increasing investment for healthcare infrastructure.
The major players operating in the Atherosclerosis Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy's Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland).